eMedicine Specialties > Neurology > Neuro-vascular Diseases

Arteriovenous Malformations

Author: H Christian Schumacher, MD, Postdoctoral Residency Fellow, Doris and Stanley Tananbaum Stroke Center, Columbia University Presbyterian Medical Center
Coauthor(s): Randolph S Marshall, MD, Co-Director, Levine Cerebral Localization Lab, Associate Professor, Department of Neurology, Division of Cerebrovascular Diseases, Columbia University Presbyterian Medical Center
Contributor Information and Disclosures

Updated: May 31, 2006

Introduction

Background

Hemorrhage from cerebral arteriovenous malformations (AVMs) represents 2% of all hemorrhagic strokes. A clear understanding of the diagnostic and treatment algorithms involved with AVM management is imperative, because AVMs are a cause of hemorrhage in young adults.

Pathophysiology

AVMs are congenital lesions composed of a complex tangle of arteries and veins connected by one or more fistulae. The vascular conglomerate is called the nidus. The nidus has no capillary bed, and the feeding arteries drain directly to the draining veins. The arteries have a deficient muscularis layer. The draining veins often are dilated owing to the high velocity of blood flow through the fistulae. How the abnormal vessels appear or exactly when the process begins is unknown. Deranged production of vasoactive proteins is under investigation as the angiogenetic link to pathophysiology.

AVMs produce neurological dysfunction through 3 main mechanisms. First, hemorrhage may occur in the subarachnoid space, the intraventricular space or, most commonly, the brain parenchyma. Second, in the absence of hemorrhage, seizures may occur as a consequence of AVM: approximately 15-40% of patients present with seizure disorder. Finally, but rarely, a progressive neurological deficit may occur in 6-12% of patients over a few months to several years. These slowly progressive neurological deficits are thought to relate to siphoning of blood flow away from adjacent brain tissue (the "steal phenomenon"), a concept that has been recently challenged. Neurological deficits may be explained alternatively by the mass effect of an enlarging AVM or venous hypertension in the draining veins.

Frequency

United States

The detection rate in the general population based on prospective data from the New York Islands AVM Study is approximately 1.34 per 100,000 person-years. The prevalence of cerebral AVM in the United States is not known. Given the low threshold for MRI neuroimaging, many patients' conditions are now discovered before they experience a brain hemorrhage.

International

Reported detection rates range between 0.89 and 1.24 per 100,000 person-years according to reports from Australia, Sweden, and Scotland. The prevalence of cerebral AVMs in Scotland has been estimated to be 18 per 100,000 person-years.

Mortality/Morbidity

Although 300,000 persons in the United States may harbor AVMs, only 12% of AVMs are estimated to become symptomatic. Death occurs in 10-15% of patients who have hemorrhage, and morbidity of various degrees occurs in approximately 50%.

  • Hemorrhage: In population-based studies, 38-70% of brain AVMs present initially with hemorrhages. The overall risk of intracranial hemorrhage in patients with known AVM is 2-4% per year. Patients presenting with a hemorrhage are at increased risk for rebleeding, particularly during the first year after the initial hemorrhage (recurrent hemorrhage rate within 12 months after initial hemorrhage: patients with hemorrhagic presentation 7-33%; patients with nonhemorrhagic presentation 0-3%). Hemorrhage rates progressively converge with time for both patients groups after 1 year. Clinical and angiographic features associated with the risk for hemorrhagic presentation are male gender, small AVM size, location in the basal ganglia or posterior fossa, deep venous drainage, single or only few draining veins, high pressure in the feeding arteries as measured during angiography, and intranidal and flow-related feeding artery aneurysms.

    Although the initial presentation of a cerebral hemorrhage may be indistinguishablefrom those of other causes of hemorrhage, the neurological deficit in AVM-related hemorrhage tends to be less severe compared with a non–AVM-related hemorrhage. Recovery of AVM-related hemorrhage tends to be better, partly because of the relatively younger age of patients with AVM and partly because of functional cerebral reorganization in patients with cerebral AVMs.
  • Seizures and epilepsy: Seizures unrelated to hemorrhage occur as the presenting symptom in 15-40% of patients with brain AVM. These may be focal or become secondarily generalized. Satisfactory treatment of seizures is usually possible with standard anticonvulsants. Presentation with seizures is associated with young age, large AVM size, lobar location (especially temporal lobe), and feeders mainly from the middle cerebral artery. Patients with brain ruptured AVM, especially if it is of cortical or subarachnoid location, are at increased risk to develop seizures and epilepsy similar to patients with this type of hemorrhages of other causes unrelated to brain AVM.
  • Headache and migraine: In the general population, headache due to a brain AVM is an extremely uncommon cause. Headache unrelated to hemorrhage occurs in 4-14% of patients with AVM and may be the presenting symptom. The headache may be typical for migraine or may be present with a less specific complaint of more generalized head pain.

Race

No racial predilection has been identified.

Sex

Both sexes are affected equally.

Age

  • Despite the presumed congenital origin of AVMs, the clinical presentation most commonly occurs in young adults.
  • AVM hemorrhage or seizure as an incident event may occur in young children or adults older than 40 years; however, childhood migraine is common.
  • A history of subtle learning disorder is elicited in 66% of adults with AVMs. This suggests early effects that are largely subclinical and do not come to medical attention.

Clinical

History

  • AVMs tend to be clinically silent until the presenting event occurs. Therefore, the diagnosis usually is made at the time of the first seizure or hemorrhage.
  • A history of minor learning disability is present in as many as two thirds of patients; such dysfunction is rarely apparent in adult life.
  • A history of headaches is present in as many as half of patients with cerebral AVM. The headaches subsequently may take the form of classic migraine or more generalized headache.
  • If seizures have occurred, a careful seizure history should be obtained. Seizures are simple, partial, or secondarily generalized.
  • The effectiveness of anticonvulsant therapy should be observed carefully and monitored before and during treatment.

Physical

  • Abnormal physical findings are rare in the absence of hemorrhage in patients with cerebral AVMs.
  • Detailed neuropsychological testing may disclose subtle right or left hemisphere dysfunction.
  • If parenchymal hemorrhage is present, the physical findings are indistinguishable from those due to intracranial hemorrhage of other causes.
  • Intraventricular hemorrhage generally produces a less severe neurological deficit than hemorrhage into other areas of the brain.
  • In the rare patients in whom focal neurological deficits are present, the deficit may reflect the location of the AVM.

Causes

  • No genetic, demographic, or environmental risk factors for cerebral AVM have been identified clearly.
  • Families with cerebral AVMs are rare, and such pedigrees have been too small to enable linkage studies. From the few family cases reported, the inheritance appears to be autosomal dominant.
  • In a small minority of cases, cerebral AVMs are associated with other inherited disorders, such as the Osler-Weber-Rendu syndrome (ie, hereditary hemorrhagic telangiectasia), Sturge-Weber disease, neurofibromatosis, and von Hippel-Lindau syndrome.

More on Arteriovenous Malformations

Overview: Arteriovenous Malformations
Differential Diagnoses & Workup: Arteriovenous Malformations
Treatment & Medication: Arteriovenous Malformations
Follow-up: Arteriovenous Malformations
Multimedia: Arteriovenous Malformations
References

References

  1. ARUBA Investigators. Unruptured brain arteriovenous malformation trial. [The Internet Stroke Center]. Feb 2006;[Full Text].

  2. ARUBA Study. Unruptured brain arteriovenous malformation trial. [ARUBA Study Site]. Feb 2006;[Full Text].

  3. Al-Shahi R, Bhattacharya JJ, Currie DG. Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS). Stroke. May 2003;34(5):1163-9. [Medline].

  4. ApSimon HT, Reef H, Phadke RV. A population-based study of brain arteriovenous malformation: long-term treatment outcomes. Stroke. Dec 2002;33(12):2794-800. [Medline].

  5. Castel JP, Kantor G. [Postoperative morbidity and mortality after microsurgical exclusion of cerebral arteriovenous malformations. Current data and analysis of recent literature]. Neurochirurgie. May 2001;47(2-3 Pt 2):369-83. [Medline].

  6. Flickinger JC, Kondziolka D, Lunsford LD. A multi-institutional analysis of complication outcomes after arteriovenous malformation radiosurgery. Int J Radiat Oncol Biol Phys. Apr 1 1999;44(1):67-74. [Medline].

  7. Halim AX, Johnston SC, Singh V. Longitudinal risk of intracranial hemorrhage in patients with arteriovenous malformation of the brain within a defined population. Stroke. Jul 2004;35(7):1697-702. [Medline].

  8. Hartmann A, Mast H, Mohr JP, et al. Determinants of staged endovascular and surgical treatment outcome of brain arteriovenous malformations. Stroke. Nov 2005;36(11):2431-5. [Medline][Full Text].

  9. Hillman J. Population-based analysis of arteriovenous malformation treatment. J Neurosurg. Oct 2001;95(4):633-7. [Medline].

  10. Hofmeister C, Stapf C, Hartmann A, et al. Demographic, morphological, and clinical characteristics of 1289 patients with brain arteriovenous malformation. Stroke. Jun 2000;31(6):1307-10. [Medline][Full Text].

  11. Maruyama K, Kawahara N, Shin M. The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med. Jan 13 2005;352(2):146-53. [Medline].

  12. Mast H, Young WL, Koennecke HC. Risk of spontaneous haemorrhage after diagnosis of cerebral arteriovenous malformation. Lancet. Oct 11 1997;350(9084):1065-8. [Medline].

  13. Nataf F, Ghossoub M, Schlienger M. Bleeding after radiosurgery for cerebral arteriovenous malformations. Neurosurgery. Aug 2004;55(2):298-305; discussion 305-6. [Medline].

  14. Ogilvy CS, Stieg PE, Awad I. AHA Scientific Statement: Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke. Jun 2001;32(6):1458-71. [Medline].

  15. Stapf C, Mast H, Sciacca RR. The New York Islands AVM Study: design, study progress, and initial results. Stroke. May 2003;34(5):e29-33. [Medline].

Further Reading

Keywords

cerebrovascular malformation, vascular malformation, AVM, cerebral AVM, stroke, cerebral hemorrhage, intracranial hemorrhage, arteriovenous malformations, cerebral arteriovenous malformations, AVMs, hemorrhagic stroke

Contributor Information and Disclosures

Author

H Christian Schumacher, MD, Postdoctoral Residency Fellow, Doris and Stanley Tananbaum Stroke Center, Columbia University Presbyterian Medical Center
H Christian Schumacher, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, and American Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Randolph S Marshall, MD, Co-Director, Levine Cerebral Localization Lab, Associate Professor, Department of Neurology, Division of Cerebrovascular Diseases, Columbia University Presbyterian Medical Center
Randolph S Marshall, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, and American Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Edward L Hogan, MD, Professor, Department of Neurology, Medical College of Georgia; Emeritus Professor and Chair, Department of Neurology, Medical University of South Carolina
Edward L Hogan, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Neurological Association, American Society for Biochemistry and Molecular Biology, Phi Beta Kappa, Sigma Xi, Society for Neuroscience, and Southern Clinical Neurological Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Howard S Kirshner, MD, Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center
Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association
Disclosure: Boehringer Ingelheim Honoraria Speaking and teaching; BMS/Sanofi Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; Novartis Consulting fee Review panel membership

CME Editor

Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital
Matthew J Baker, MD is a member of the following medical societies: American Academy of Neurology
Disclosure: Nothing to disclose.

Chief Editor

Helmi L Lutsep, MD, Professor, Department of Neurology, Oregon Health and Science University; Associate Director, Oregon Stroke Center
Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association
Disclosure: Co-Axia Consulting fee Review panel membership; Talecris Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Boehringer Ingelheim Honoraria Speaking and teaching; Boston Scientific Honoraria Speaking and teaching; Concentric Medical None Review panel membership; Northstar Neuroscience  Review panel membership; ev3 Consulting fee Review panel membership

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.